This week, rheumatologists and rheumatology stakeholders from the American College of Rheumatology (ACR) took to Capitol Hill to advocate on pressing issues in rheumatology care, such as the rising costs of treatment and lack of access to care.
This week, rheumatologists and rheumatology stakeholders from the American College of Rheumatology (ACR) took to Capitol Hill to advocate on pressing issues in rheumatology care, such as the rising costs of treatment and lack of access to care.
ACR members urged lawmakers to support legislation that would limit the use of step therapy, grow the rheumatology workforce, create more transparency in drug pricing, and hold pharmacy benefit managers accountable for their part in practices that have increased out-of-pocket costs for patients.
Additionally, ACR encouraged leaders to support the following legislation that would address the increasing costs and barriers in access, among others:
Finally, ACR urged members of the House and Senate Appropriations Subcommittees on Defense to create a line item in the Congressionally Designated Medical Research Program (CDMRP) for arthritis at the Department of Defense using an existing $20 million in funds. The creation of this program would address the needs of active duty military personnel and veterans who have osteoarthritis and other rheumatic diseases.
“We are at a critical juncture in rheumatology care…the rheumatology workforce is not growing fast enough to keep up with demand and too many of our patients struggle to access and afford the breakthrough therapies they need to manage their pain and avoid long-term disability,” said David Daikh, MD, PhD, president of ACR, in a prepared statement.
The American College of Rheumatology’s Advocacy Leadership Conference was held on May 16 to May 17, 2018 in Washington, D.C.
CHMP Pushes 3 Biosimilars Forward, Spelling Hope for Ophthalmology, Supportive Care Markets
February 6th 2025The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended 3 biosimilars and new indications for reference biologics, moving them closer to final European approval and expanding patient access.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
The Banking of Biosimilars: Insights From a Leading Health Economist
February 4th 2025Biosimilars have the potential to reduce health care costs and expand patient access, but economic and policy barriers affect adoption, explored James D. Chambers, PhD, MPharm, MSc, associate professor at the Tufts Medical Center Institute for Clinical Research and Health Policy Studies, in an interview.